AstraZeneca's Enhertu Shows Promise in HER2-Low Breast Cancer at ASCO
TL;DR Summary
Enhertu, a cancer drug developed by Daiichi Sankyo and AstraZeneca, has shown in clinical trials to stall tumor growth in metastatic breast cancer for over a year, significantly longer than standard chemotherapy. This breakthrough could change the standard of care for hormone receptor-positive, metastatic breast cancer, benefiting patients with even minimal HER2 protein expression.
- At ASCO, AstraZeneca reports strong data for breast cancer drug STAT
- ASCO: AstraZeneca, Daiichi's Enhertu looks to make history again in HER2-ultralow breast cancer FiercePharma
- Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Nature.com
- Astra's Enhertu delays breast cancer in patients with low HER2 levels AOL
- With new Enhertu data, an ADC could overtake chemo in breast cancer Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
80%
276 → 54 words
Want the full story? Read the original article
Read on STAT